There have been dramatic advancements in chronic lymphocytic leukemia (CLL) in recent years, including the introduction of a multitude of novel agents, which has opened up a field of new considerations, as discussed here Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany. Prof. Stilgenbauer gives his perspective on drug resistance, and the sequence and combination of therapy, in CLL in this era of novel agents. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
